© 2017 by Mobility Care Aids                    Registered Address:

                                         MobilityCareAids.co.uk
                                      20-22 Wenlock Road
                                            London, United Kingdom
                       N1 7GU      
                                                   Company Number: 06767778

                                                                           VAT Number: 947 1371 12

                                      

                                        

Call us on 0208 123 1977

  • Facebook App Icon
  • Twitter App Icon
  • Google+ App Icon

March 26, 2019

Please reload

Recent Posts

Creating the right environment for someone who is living with dementia

March 26, 2019

1/10
Please reload

Featured Posts

Arthritis superdrug gives new hope after a powerful drug made available on the NHS

December 3, 2012

 

Thousands of arthritis sufferers crippled by rheumatoid arthritis were earlier this year given new hope after a powerful drug was made available on the NHS.

The drug tocilizumab, (Brand Name: RoActemra) was approved for patients with the autoimmune disease who are not responding to other treatments. The decision made by the National Institute for Health and Clinical Excellence means that approximately 40,000 sufferers of the condition can now benefit from its’ use.

Professor Paul Emery, Arthritis Research UK Professor of Rheumatology at Leeds University, said: “This recommendation offers the chance of r­emission to the tens of thousands of patients who do not respond to standard rheumatoid arthritis treatments.”

Prior to this, patients in England and Wales had been denied the £9,000 a year drug because of cost. But in 2010 NICE approved its use as a “last resort” and earlier this year NICE went one step further.

The drug is a laboratory manufactured antibody that blocks a molecule called ­interleukin 6, associated with many inflammatory processes. Trials showed RoActemra, when given with drug methotrexate, offers clinical remission rates almost six times higher after a year than methotrexate alone.

Rheumatoid arthritis is a condition which attacks the body’s joints and affects around 646,000 people in the UK.


For more information on this, please click on:

http://www.nras.org.uk/about_rheumatoid_arthritis/newly_diagnosed/which_drugs_are_used/what_is_roactemra/_tocilizumab.aspx

 

Share on Facebook
Share on Twitter